Raymond James set a $5.50 target price on ZIOPHARM Oncology (NASDAQ:ZIOP) in a research note published on Friday morning, BayStreet.CA reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

ZIOP has been the subject of a number of other reports. Jefferies Financial Group started coverage on ZIOPHARM Oncology in a research note on Friday, June 19th. They set a buy rating and a $7.00 price target for the company. ValuEngine raised ZIOPHARM Oncology from a hold rating to a buy rating in a research note on Friday, May 1st. HC Wainwright reissued a buy rating and set a $5.50 price target (down from $6.50) on shares of ZIOPHARM Oncology in a research note on Monday, May 11th. Laidlaw reissued a buy rating and set a $7.50 price target on shares of ZIOPHARM Oncology in a research note on Sunday, June 21st. Finally, Cantor Fitzgerald reissued a market perform rating and set a $6.00 price target on shares of ZIOPHARM Oncology in a research note on Sunday, June 21st. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $5.75.

NASDAQ ZIOP opened at $3.26 on Friday. The firm has a market cap of $722.16 million, a price-to-earnings ratio of -4.66 and a beta of 2.58. The company has a quick ratio of 11.56, a current ratio of 11.56 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $3.23 and a 200-day moving average price of $3.30. ZIOPHARM Oncology has a twelve month low of $1.79 and a twelve month high of $7.25.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). During the same period in the prior year, the business posted ($0.08) earnings per share. Research analysts expect that ZIOPHARM Oncology will post -0.35 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the company. State Street Corp lifted its stake in shares of ZIOPHARM Oncology by 7.8% in the 1st quarter. State Street Corp now owns 6,398,385 shares of the biotechnology company’s stock valued at $15,676,000 after purchasing an additional 460,794 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of ZIOPHARM Oncology by 83.9% in the 1st quarter. Royal Bank of Canada now owns 13,927 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 6,353 shares during the last quarter. Public Employees Retirement Association of Colorado raised its holdings in shares of ZIOPHARM Oncology by 41.9% in the first quarter. Public Employees Retirement Association of Colorado now owns 39,565 shares of the biotechnology company’s stock worth $97,000 after buying an additional 11,680 shares during the period. Morgan Stanley raised its holdings in shares of ZIOPHARM Oncology by 13.5% in the first quarter. Morgan Stanley now owns 1,339,584 shares of the biotechnology company’s stock worth $3,282,000 after buying an additional 158,882 shares during the period. Finally, Voloridge Investment Management LLC purchased a new stake in shares of ZIOPHARM Oncology in the first quarter worth approximately $194,000. 46.13% of the stock is owned by institutional investors and hedge funds.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Featured Story: Average Daily Trade Volume – What You Need to Know

Analyst Recommendations for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.